AKRO — Akero Therapeutics Share News
0.000.00%
Last trade - 00:00Akero's lead drug helps improve scarring in fatty liver disease patients
Brief: Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
Nash Drug Developers Fall As Lilly's Weight: loss drug shows promise in trial
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
U.S. STOCKS ON THE MOVE-DocuSign, Eli Lilly, Sunworks
NASH drug developers fall as Lilly's drug shows promise in trial
Brief: Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
89Bio down on pricing $150 mln stock offering
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Cisco, Microsoft
Brief: Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX
Akero Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Dynatrace, Fleetcor Technologies, Tanger Factory Outlet Centers
U.S. RESEARCH ROUNDUP-American Financial Group, EverCommerce, Texas Instruments
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
89bio falls as rival Akero's NASH drug fails in mid-stage study
Akero slides as NASH drug fails to meet main goal in study
U.S. STOCKS ON THE MOVE-PepsiCo, Electronic Arts, Honeywell